The reporter learned from Guangzhou Pharmaceutical Group that the Ministry of Industry and Information Technology recently released in the “Application Case Collection of High-Value Scenarios of Artificial Intelligence”, the “Development and Application of AI Smart Devices for the Creation of New Drugs Driven by Domestic Computing Power” project, which was jointly declared by Guangzhou Pharmaceutical Group in collaboration with Huawei and First Core Molecule, was selected, making it the only project selected in the pharmaceutical industry in China in this case collection. According to reports, the project has completed proof-of-concept tests and is expected to shorten the discovery cycle for emerging compounds from 12 to 18 months to 1 to 3 months, and increase pre-clinical efficiency by more than doubling.

The reporter learned from Guangzhou Pharmaceutical Group that the Ministry of Industry and Information Technology recently released in the “Application Case Collection of High-Value Scenarios of Artificial Intelligence”, the “Development and Application of AI Smart Devices for the Creation of New Drugs Driven by Domestic Computing Power” project, which was jointly declared by Guangzhou Pharmaceutical Group in collaboration with Huawei and First Core Molecule, was selected, making it the only project selected in the pharmaceutical industry in China in this case collection. According to reports, the project has completed proof-of-concept tests and is expected to shorten the discovery cycle for emerging compounds from 12 to 18 months to 1 to 3 months, and increase pre-clinical efficiency by more than doubling.